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The introduction of highly sensitive methods, such as transvaginal sonography and measurement of serum β-human chorionic 
gonadotropin, has dramatically improved ectopic pregnancy diagnosis in recent years. Early diagnosis is the key to successful 
and conservative management of women with ectopic pregnancy; however, approximately 50 percent of such women are initially 
misdiagnosed, resulting in significant morbidity and mortality. In order to improve diagnosis, several serum markers are being 
investigated including progesterone, CA 125, pregnancy-associated plasma protein-A, vascular endothelial growth factor, and 
maternal creatine kinase. Measurement of serum vascular endothelial growth factor, alone or together with other markers, could 
be a promising method for earlier and more accurate differential diagnosis. However, the clinical applicability of these findings 
remains to be evaluated in larger prospective studies.
KEYWORDS: Ectopic pregnancy; First trimester pregnancy; Progesterone; Vascular endothelial growth factor; Pregnancy-
associated plasma protein A.
INTRODUCTION 
Ectopic pregnancy (EP), defined as the implantation 
and development of the gestational sac outside of the 
uterine cavity, represents the fourth most frequent cause of 
maternal death in the United Kingdom.1
The increased incidence of EP in recent decades2,3 
can be attributed to a growing number of risk factors 
(higher prevalence of sexually transmitted diseases, late 
primiparity, the use of levonorgestrel as an emergency 
contraceptive method, the more frequent use of assisted 
reproduction technologies, and increased tubal sterilization 
practices and subsequent attempted reversals4-8) and 
improved diagnostic methods (transvaginal ultrasound and 
serum measurement of the beta subunit of human chorionic 
gonadotrophin - β-hCG4-6,9-11).
Early diagnosis of first trimester hemorrhage presents 
an important challenge12. Transvaginal ultrasounds and 
serial β-hCG determinations are currently the most 
common methods used for diagnosis.12-15 Despite the use 
of high-resolution transvaginal sonography and sensitive 
assays for β-hCG, it is believed that 40 to 50% of cases 
are initially misdiagnosed.16 Transvaginal sonography 
has been proposed as helpful only when intrauterine 
gestation or an adnexal mass is observed,17,18 and serum 
β-hCG measurements can distinguish a normal intrauterine 
pregnancy (IUP) from a non-viable pregnancy, but cannot 
distinguish arrested IUP from EP.13,15,18,19 Ultrasound 
is inconclusive in up to 18% of women for whom 
measurement of serial β-hCG concentrations is necessary 
to guide management. Serum β-hCG measurement is the 
mainstay of rapid and early pregnancy diagnosis and is an 
accepted biochemical marker for successful trophoblastic 
implantation.20 Abnormal gestation is suspected when serial 
β-hCG values fall or do not rise appropriately.21 Once 
β-hCG is trophoblast-dependent, its serum concentration is 
significantly higher in women with normal IUP, but serial 
β-hCG determination cannot accurately separate arrested 702
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IUP from EP since decreased or decelerated increases 
in β-hCG concentrations cannot be used to discriminate 
between miscarriage and an EP. Consequently, β-hCG 
measurement is not practical when the patient presents for 
an emergency evaluation.
For this reason, several serum markers have been 
under investigation to permit earlier diagnosis of EP, 
and include progesterone,12,13,15,21-25 Ca- 125, pregnancy-
associated plasma protein A (PAPP-A),12,13,20 serum vascular 
endothelial growth factor (VEGF) 12-15,17, and serum creatine 
kinase (CK).14,26,27
The aim of this article is to review the role of several 
maternal serum substances as markers of EP.
PROGESTERONE 
In contrast with β-hCG concentrations, serum 
progesterone levels are stable for the first 8–10 weeks 
of gestation,28,29 and previous studies demonstrated 
that concentrations are higher in normal IUP.22-24,30 
Consequently, serum progesterone levels may be helpful 
for evaluation of suspected EP if they are very high or very 
low.21,22
To assess the accuracy of single serum progesterone 
measurement in the diagnosis of EP, a meta-analysis 
was performed incorporating 26 studies evaluating the 
performance of single serum progesterone as a diagnostic 
tool.23 The meta-analysis revealed that low levels of 
serum progesterone (≤ 5 ng/ml) could be used to correctly 
diagnose pregnancy failure, but that this cutoff was unable 
to discriminate between EP and nonviable intrauterine 
pregnancy. Sensitivities ranged from 44 to 100 percent, 
depending on the threshold. In 12 studies comprising a 
total of 1,107 women, only 2.6% of women with EP had 
progesterone levels greater than 20 ng/ml; in 13 studies, only 
five of 1,615 women (0.3%) with progesterone levels less 
than 5 ng/ml had a viable IUP.23 The authors concluded that 
this hormone could be used to identify women at risk for EP, 
but could not distinguish between EP and abnormal IUP.
Both high (> 22 ng/ml) and low (≤ 5 ng/ml) cutoff 
points have been assessed for their ability to correctly 
identify nonviable and ectopic pregnancies; serum 
progesterone levels ≤ 5 ng/ml could apparently be used to 
predict EP with 70% to 90% sensitivity and 30% to 99% 
specificity.24,31
Serum progesterone measurements may also have 
prognostic efficacy when associated with serum β-hCG 
concentrations. Patients with progesterone levels below 10 
ng/ml (31.8 nmol/L) and hCG levels below 1,500 mIU/L 
are more likely to demonstrate spontaneous resolution of 
EP.32
Rapid progesterone analysis can identify two important 
groups of women in the emergency room presenting first-
trimester vaginal bleeding/pelvic pain: those with stable 
pregnancy with progesterone levels > 22 ng/ml and those 
with levels < 5 ng/ml. The first group has a high (but not 
definite) probability of viable intrauterine pregnancy, 
whereas the second almost certainly has a nonviable 
pregnancy. Invasive diagnostic testing (e.g. dilatation and 
curettage) could be postponed in the former patients, but 
offered to the latter, as could treatment with methotrexate 
(without fear of interrupting a potentially viable IUP).
PAPP-A
Normal IUP is associated with production of many 
placenta proteins13. Shortly after implantation, β-hCG 
can be found in the maternal circulation20. Trophoblastic 
tissue continues to synthesize and secrete various proteins 
throughout pregnancy, including leukemia inhibiting 
factor (LIF), serum specific protein-1 (SP1), human 
placental lactogen (HLP), and pregnancy-associated plasma 
protein-A (PAPP-A) . 12,13,20 The biological function of these 
proteins is unclear, but they reflect the biosynthetic capacity 
of the decidualized endometrium.33
PAPP-A is synthesized by stromal cells. PAPP-A 
concentrations increase progressively to term, possibly 
as a spontaneous effect of the abundance of stromal cells. 
However, this substance can also found in nonpregnant 
persons in extrauterine sites including follicles, follicular 
fluid, luteal cells, and fallopian tubes. In men, this protein 
is present in seminal vesicles and seminal fluid.33
Previous studies demonstrated that placental protein 
levels are markedly reduced in EP when compared to 
normal IUP at the same gestational age13,34-36. Decreased 
circulating levels of proteins observed in EP have been 
proposed to reflect a smaller syncytiotrophoblastic mass.13
Sinosich et al.34 studied 116 patients, including 87 
non-pregnant women, 16 patients with tubal pregnancies, 
and 13 women with IUP. The authors measured PAPP-A, 
hCG, and SP1 concentrations in 164 serum samples and 
29 tissue samples obtained from these women. In the tubal 
pregnancy group, only two of the 47 serum samples were 
positive for PAPP-A. The authors indicated that clinical 
evidence of EP (vaginal bleeding, abdominal pain) and 
severely decreased or absent serum PAPP-A levels in 
women with a positive pregnancy test suggest a diagnosis 
of EP as the main possibility.
Sjöberg35 measured serum PAPP-A concentrations in 
164 patients presented to gynecologic emergency services: 
124 women had EP and 40 had intrauterine abortions. 
The PAPP-A levels in 136 women with normal IUP were 703
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compared with those of 460 non-pregnant women. Serum 
PAPP-A levels were lower in the EP and intrauterine 
abortion groups compared to the normal pregnancy group; 
they were undetectable in 82% of the EP group and 55% 
of the intrauterine abortion group. Thus, the probability 
that a pregnant patient with undetectable PAPP-A levels 
has an EP was calculated to be 30%; the probability of an 
intrauterine abortion was calculated to be 29%. Although 
PAPP-A levels were found to be lower in individuals with 
ectopic pregnancies and intrauterine abortions compared 
to those with normal pregnancies, PAPP-A measurements 
cannot be used to distinguish between EP and intrauterine 
abortion.35 Tornehave et al. examined the tissue distribution 
and intensity of immunohistochemical staining for hCG, 
SP-1, and PAPP-A in trophoblastic and decidualized 
endometrial tissues of 10 women with EP. Staining 
was then correlated with serum concentrations of these 
substances. All 10 women showed strong hCG and SP-1 
staining in the syncytiotrophoblast that was apparently 
unrelated to maternal levels of hCG and SP-1. In contrast, 
maternal PAPP-A levels seemed to correlate with the 
intensity and distribution of PAPP-A staining. Circulating 
PAPP-A was undetectable in 4 patients, and below the 
10th percentile in the remaining 6. PAPP-A could not be 
detected in any of the decidualized endometrial tissues 
studied using immunohistochemical techniques.36
Recently, Daponte et al.12 evaluated whether serum 
concentrations of the non-placental markers VEGF, 
glycodelin, and progesterone and placental markers 
PAPP-A, HPL, and LIF differed in EP compared to 
abnormal IUP. A prospective study was conducted 
comprising 21 patients with failed pregnancy (treated by 
dilatation and curettage – mean gestational age 7.15 weeks) 
and 27 women with EP (treated by laparoscopy - mean 
gestational age 7.3 weeks). Serum PAPP-A, progesterone, 
LIF, HPL, and glycodelin levels did not significantly differ 
between the two groups. As a consequence, they concluded 
that serum concentrations of placental markers such as 
PAPP-A, HLP, and LIF could not be used to differentiate 
EP from abnormal IUP.12 
VEGF
VEGF is a potent angiogenic factor that acts as a 
modulator of vascular growth, remodeling, and permeability 
in the endometrium, decidua, and trophoblast, as well as 
during vascular development in the embryo, all of which 
are crucial processes related to normal implantation and 
placentation.37 VEGF expression and secretion can be 
induced by cytokines, growth factors, hormones, and local 
conditions such as hypoxia.37,38 Cellular VEGF production 
has been shown to increase under hypoxic conditions. 
The implantation environment in the oviduct is very 
different from that of the well-vascularized endometrium, 
and production and secretion of VEGF may be affected 
in EP. Daniel et al. first reported a difference in maternal 
serum VEGF levels between women with EP, abnormal IUP, 
and normal IUP. A prospective study comprising 20 women 
with EP showed that serum VEGF levels were higher in 
these women when compared to women with abnormal 
intrauterine pregnancies. A serum VEGF level > 200 ng/
ml was suggested for discrimination between intrauterine 
and extrauterine pregnancies with a specificity of 90% 
and PPV of 86%, and between abnormal intrauterine and 
extrauterine pregnancies with a specificity of 80% and PPV 
of 86%.38 Similarly to the previous study, Felemban et al.15 
concluded that VEGF concentrations are higher in women 
with EP than in those with normal and arrested IUP. Forty-
five pregnant women were studied at 5 weeks of gestation, 
and a VEGF cut-off concentration of 200 pg/ml was found 
to distinguish normal intrauterine pregnancies from EP 
with a sensitivity, specificity, and PPV of 88%, 100%, and 
100%, respectively. For discrimination of EP and abnormal 
intrauterine pregnancies, the sensitivity, specificity, and 
PPV were 87.5%, 75%, and 77.8%, respectively.15 Daponte 
et al.12 described higher serum VEGF concentrations in 
women with EP (median 227.2 pg/ml) than in those with 
abnormal intrauterine pregnancy (median 107.2 pg/ml) 
(P < 0.001). The authors concluded that VEGF serum 
concentrations might be a useful marker for differentiating 
between EP and abnormal IUP, and suggested 174 pg/ml 
as the cut-off value for EP diagnosis.12
On the other hand, some groups have found conflicting 
results. Ugurlu et al.39 evaluated whether serum 
measurement of VEGF could be used for differentiation of 
EP from spontaneous miscarriages and normal intrauterine 
pregnancies. The study included 85 patients separated 
into three groups: 29 pregnant women who desired 
elective termination, 28 patients with previously presumed 
miscarriage, and 28 women with suspected EP. Serum 
VEGF concentrations did not show statistical differences 
among the women in the three groups (P=0.27). Therefore, 
the authors concluded that serum VEGF measurements 
should not be used to discriminate between EP and non-
EP pregnancies in clinical practice. In another study, blood 
samples were collected from 140 women with suspected 
EP (pelvic pain and/or vaginal bleeding during the first 
trimester of pregnancy); EP diagnosis was confirmed in 
62 cases. There was no difference in VEGF concentration 
between patients with ectopic or intrauterine pregnancies.40 
Kucera-Sliutz et al.14 performed a prospective study 
comparing serum VEGF levels among 84 women with 704
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abnormal intrauterine and EP at 6 weeks of gestation (42 
women in each group). They analyzed whether serum 
VEGF levels >200 pg/ml could discriminate between 
abnormal intrauterine pregnancies and EP, and found that 
VEGF concentrations were not significantly different 
between women with abnormal intrauterine pregnancies 
(median, 198.5 pg/ml; range, 0-701.6) and those with EP 
(median, 211.2 pg/ml; range 0-628.8). When serum VEGF 
threshold concentrations >200 pg/ml were used, abnormal 
intrauterine pregnancy could be distinguished from EP 
with a sensitivity, specificity, and PPV of 56%, 51%, and 
53%, respectively. The authors concluded that VEGF 
could not discriminate ectopic from abnormal intrauterine 
pregnancies at 6 weeks of gestation, and thus should not be 
used for clinical management.14
In an attempt to characterize factors affecting production 
and secretion of VEGF in EP, expression of VEGF mRNA 
and the VEGF receptors KDR and flt-1 were measured 
in implanted and non-implanted sites of the oviduct in 
women with EP41. Expression was significantly higher in 
the implanted site in humans with EP when compared to 
the non-implanted site, suggesting that VEGF may play an 
important role in placentation and vascular development of 
embryos during EP.
Mueller et al performed a prospective clinical study 
to evaluate whether combinations of different placental 
and nonplacental markers could differentiate EP from 
normal intrauterine pregnancy. Serum values of VEGF 
were significantly increased in EP, and a combination 
of three independent markers using the formula VEGF/
(PAPP-A x Progesterone) was found to be superior to 
single marker measurements for discrimination between 
normal intrauterine pregnancy and EP (sensitivity of 97.7% 
and specificity of 92.4%).13 
CREATINE KINASE (CK)
The lack of a submucosal layer in the fallopian tube 
allows the zygote to penetrate the epithelium and lay next 
to the muscular layer in tubal pregnancies. The trophoblast 
usually invades the muscle layer and maternal blood vessels 
are eroded, allowing muscle cell products such as CK to 
enter the circulation;26 therefore, increased serum CK levels 
are normal during EP.26,27 The pathology of arrested IUP and 
pelvic inflammatory disease are different, although both 
demonstrate no change in CK concentration. For unknown 
reasons, increases in CK are also not observed during 
appendicitis. Therefore, the CK assay has been proposed to 
be a potentially important diagnostic test for EP.
Existing evidence suggests elevated CK as a tool for 
diagnosis of ectopic pregnancy (EP). A prospective study 
compared serum CK levels in 90 women divided into five 
groups: 20 patients with tubal pregnancies, 20 patients with 
missed abortions, 20 age- and time of gestation-matched 
patients with normal pregnancies (controls), 20 patients 
with pelvic inflammatory disease, and 10 patients with 
acute appendicitis. The CK levels in women in the tubal 
pregnancy group were significantly higher than in the 
other four groups (P < 0.0001). It was thus concluded that 
maternal serum CK could be an important biochemical 
marker in suspected tubal pregnancy.26
Saha et al.27 performed a study comprising 40 women; 
twenty subjects had proven EP and 20 subjects with 
confirmed IUP matched for gestational age were used 
as controls. Total serum CK levels were found to be 
significantly higher in the EP group as compared to the 
controls (p < 0.001), suggesting that this test might be used 
as a indicator for EP.27
Similarly, Katsikis et al. studied 40 women with EP; 20 
with intrauterine abortive gestation and 20 normal pregnant 
women (controls). Total serum CK levels were measured 
at the time of presentation and 24 hours after surgery. 
Women with EP had significantly higher CK concentrations 
compared to women with intrauterine abortive pregnancies 
and controls. ROC curves demonstrated significant 
discriminatory capability of increased CK for EP diagnosis, 
suggesting that CK concentrations could be used to predict 
EP.42
In contrast, recent studies have demonstrated poor 
sensitivity and positive predictive values for this test, 
suggesting that it is insufficient alone for use in clinical 
practice.25,43,44 A prospective study involving 56 patients 
divided into 4 groups was conducted in order to assess the 
utility of CK measurement in the diagnosis of EP. The study 
enrolled 10 patients with asymptomatic tubal pregnancy, 11 
patients with symptomatic tubal pregnancy, 20 patients 
with normal IUP, and 15 patients with threatened IUP. 
No significant difference was observed in the median CK 
values associated with normal pregnancies or threatened 
abortion when compared to asymptomatic or symptomatic 
tubal pregnancies, suggesting that serum CK is not a useful 
biochemical marker for EP diagnosis.43
In another study, serum CK concentrations were 
obtained from patients with EP prior to surgery. Controls 
consisted of patients with positive pregnancy tests 
complicated by vaginal bleeding and/or abdominal pain. 
There was a small, but significant difference in serum 
CK means between both groups (p=0.04). For patients 
with EP, the degree of tubal distention, implantation site, 
and presence of tubal rupture did not affect the CK value, 
thereby limiting the clinical significance of this test. The 
authors stated that the serum CK level was statistically 705
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higher in EP patients than in controls, but the CK value 
distribution curve for EP was broad and overlapped with 
the control curve, indicating that the sensitivity and positive 
predictive value of this test were poor.44
CA 125
Cancer  antigen  125  (CA  125)  is  an  antigenic 
determinant  present  on  a  high  molecular  weight 
glycoprotein recognized by a monoclonal antibody that was 
raised using an ovarian cancer cell line as an immunogen.45 
Serum CA 125 levels reach their highest point during the 
first trimester of pregnancy, between the sixth and seventh 
weeks, and fall to non-pregnant values during the second 
and third trimester.46 Elevated CA 125 levels in the maternal 
serum have been shown to originate from decidual cells 
affected by chorionic invasion or placental separation.
Although some studies indicate that serum CA 125 
levels do not predict spontaneous miscarriage in the first 
trimester of pregnancy,47 there is inconsistent evidence 
regarding the use of CA 125 to distinguish between 
intrauterine and ectopic pregnancies.
Some authors reported that serum CA 125 levels were 
significantly lower in EP as compared to intrauterine 
pregnancies. Katsikis et al.48 investigated the predictive 
value of progesterone and CA 125 for the diagnosis of EP 
and inevitable miscarriage. Forty women with EP, 20 with 
intrauterine abortive gestation, and 20 normal pregnant 
women were studied. Women with EP had significantly 
lower progesterone concentrations as compared to both 
women with intrauterine abortive pregnancies and controls. 
Women with intrauterine abortions had significantly higher 
CA-125 levels as compared to the other two groups. It 
was thus concluded that measurement of progesterone 
and CA 125 levels were useful for discriminating ectopic 
and intrauterine abortive pregnancies from normal 
gestations. Kobayashi et al.49 measured serum CA 125 
levels in 13 women with intrauterine pregnancies, nine 
with spontaneous abortions, three with hydatidiform moles, 
and 15 with EP. Serum CA 125 levels were high in patients 
with normal pregnancies (mean 154 U/ml, ± SD 169 U/
ml), spontaneous abortions (244 U/ml, ± 258 U/ml), and 
hydatidiform moles (54 U/ml, ± 16 U/ml). In contrast, 
CA 125 levels were low in patients with EP (33 U/ml, ± 
25 U/ml). The difference between serum CA 125 levels 
in intrauterine pregnancy and EP was related to different 
amounts of decidual tissues at the site of trophoblastic 
invasion.
Sadovsky et al.50 measured serum concentrations of CA 
125 in 27 women with EP and compared them with those 
measured in 17 women with intrauterine pregnancies; all 
participants were in their first trimester. The results showed 
that women with EP (ruptured or unruptured) were more 
likely to have elevated levels of serum CA 125 than women 
with intrauterine pregnancies. 
However, some studies showed that serum CA 125 
measurements failed to discriminate between spontaneous 
miscarriage, EP, and normal pregnancy. Schmidt et al.,51 
in a larger and more recent study, assessed the diagnostic 
value of maternal CA 125 in patients with symptomatic 
first trimester pregnancy. The authors followed 168 patients 
presenting between gestational weeks 6 and 12 comprised 
of 29 patients with EP, 50 patients with missed abortions, 
38 patients with incomplete spontaneous abortions, 33 
patients with imminent abortions, and 18 women with 
normal pregnancies and no history of endometriosis or 
ovarian mass. Patients with vaginal bleeding usually had 
higher median CA 125 values (38 IU/ml; range 1.3-540) 
than non-bleeding patients (17.8 IU/ml; range 1.0-157). No 
significant differences were found between median serum 
CA 125 levels in normal pregnancy and EP [25.5 IU/ml 
(range 3.2-97) and 26 IU/ml (range 1.3-157), respectively]. 
They concluded that single serum measurements of CA 125 
in symptomatic first trimester pregnant patients failed to 
discriminate between spontaneous abortion, ectopic, and 
normal pregnancies.
Condous et al.52 evaluated the role of maternal serum 
CA 125 levels in predicting the outcome of pregnancies 
of unknown location (PUL). The final outcome of each 
pregnancy of unknown location was established and 
defined as failing PUL, intrauterine pregnancy, EP, 
or persisting PUL. Two hundred ninety-seven women 
were recruited: 153 with failing PUL (51.5%), 116 with 
intrauterine pregnancies (39.1%), and 28 with EP (9.4%). 
Serum CA 125 levels were measured at 0 and 48 h, and 
the values obtained at the time of presentation and change 
in levels after 2 days were used for the analysis. The 
authors concluded that routine use of serum CA 125 in the 
management of women with PUL is not advocated because 
absolute levels of maternal serum CA 125 at defined times 
could not be used to predict the outcome of PUL.
CONCLUSIONS
Early EP diagnosis (before rupture) permits conservative 
treatment, allowing for subsequent preservation of patient 
fertility. Investigation of new serum markers could result 
in earlier diagnosis, leading to timely implementation of 
medical treatment and prevention of tubal rupture and its 
complications.
In clinical practice, progesterone cannot be used as 
an additional diagnostic test since a single measurement 706
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cannot discriminate between abnormal IUP and EP. 
Although PAPP-A, maternal serum CK, and CA 125 
concentrations were shown to be helpful for EP differential 
diagnosis, they do not represent methods of choice. 
VEGF is a promising marker for EP diagnosis. Some 
studies have demonstrated that VEGF measurement, as a 
single value or in combination with other markers, could 
significantly differentiate between EP and abnormal IUP 
during early weeks of gestation. Despite these data, the 
clinical applicability of VEGF measurement remains to be 
evaluated in larger prospective studies.
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